The first line of estrogen receptor (ER)-positive breast cancer treatment in the clinic is endocrine therapy, where aromatase inhibitors (AIs) and antiestrogen drugs, respectively, block estrogen formation and ER activity [196]. Here, CYP19A1 is linked to breast carcinoma.